Skip to content
Study details
Enrolling now

Smoking Cessation With Varenicline in Schizophrenia

Corporal Michael J. Crescenz VA Medical Center
NCT IDNCT03495024ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

10

Study length

about 1.5 years

Ages

18–75

Locations

1 site in PA

What this study is about

Researchers are testing if stopping smoking with varenicline helps reduce neurological side effects from antipsychotic medications. The trial will involve 10 people with schizophrenia who are smokers and have a condition called tardive dyskinesia while taking antipsychotics. Researchers will monitor changes in smoking status and neurological symptoms over 546 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Varenicline

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

varenicline

Drug routes

oral (Oral Tablet)

Body systems

Psychiatry / Mental Health